Bangalore, India — (PRESS RELEASE JET) — 11/01/2017 — Fabry Disease – Pipeline Review, H2 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.
Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called globotriaosylceramide) in blood vessel walls throughout the body. Symptoms include pain, diarrhea, nausea, kidney problems, tinnitus, irregular heartbeat, and leaky heart valves. Treatment includes enzyme replacement therapy (ERT).
Fabry Disease – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fabry Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fabry Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fabry Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3, 2 and 4 respectively.
Fabry Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Fabry Disease (Genetic Disorders).
– The pipeline guide reviews pipeline therapeutics for Fabry Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Fabry Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Fabry Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Fabry Disease (Genetic Disorders)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Fabry Disease (Genetic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Fabry Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Spanning over 81 pages “Fabry Disease – Pipeline Review, H2 2017” report covers Introduction, Report Coverage, Fabry Disease – Overview, Fabry Disease – Therapeutics Development, Pipeline Overview, Fabry Disease – Therapeutics Assessment, Fabry Disease – Companies Involved in Therapeutics Development, Fabry Disease – Drug Profiles, Product Description, Fabry Disease – Dormant Projects, Appendix. This report Covered Companies – Amicus Therapeutics Inc, Genzyme Corp, greenovation Biotech GmbH, Idorsia Ltd, JCR Pharmaceuticals Co Ltd, Neuraltus Pharmaceuticals Inc, Pharming Group NV, Protalix BioTherapeutics Inc, Resverlogix Corp, Sangamo Therapeutics Inc, Shire Plc.
For more information Visit at: http://www.drugpipeline.net/global-markets-direct/fabry-disease-pipeline-review-h2-2017
Find all Pharma and Healthcare Reports at – http://www.drugpipeline.net/catalog/pharma-healthcare
Leiomyosarcoma – Pipeline Review, H2 2017 – Visit at – http://www.drugpipeline.net/global-markets-direct/leiomyosarcoma-pipeline-review-h2-2017
Periodontitis – Pipeline Review, H2 2017 – Visit at – http://www.drugpipeline.net/global-markets-direct/periodontitis-pipeline-review-h2-2017
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.
Powered by WPeMatico